FDA OKs Can-Fite’s Plan to Study Piclidenoson in Kids With Psoriasis
The U.S. Food and Drug Administration (FDA) has green lighted Can-Fite’s plan to include children with psoriasis in studies of Piclidenoson, a small molecule, adenosine A3 receptor (A3AR) agonist. The Pediatric Study Plan would allow enrollment of children with psoriasis to Can-Fite’s upcoming Phase 3 pivotal clinical psoriasis studies, aiming at registration of Piclidenoson with both the FDA […]